Department of Neurosurgery, Jining First People's Hospital, Jining, 272011, Shandong Province, China.
Department of Neurosurgery, Jining First People's Hospital, Jining, 272011, Shandong Province, China.
Biochem Biophys Res Commun. 2019 Jan 22;508(4):1074-1081. doi: 10.1016/j.bbrc.2018.12.050. Epub 2018 Dec 13.
Long non-coding RNA FOXD2-AS1 (FOXD2-AS1) has been reported to be involved in several tumors as a potential oncogene. However, its expression pattern and biological function in glioma have not been investigated. In this study, we found that FOXD2-AS1 expression was significantly up-regulated in both glioma tissues and cell lines. Additionally, CREB1 could bind directly to the FOXD2-AS1 promoter region and activate its transcription. High FOXD2-AS1 expression was significantly correlated with advanced WHO grade, KPS score and the shorter survival time of glioma patients. Next, luciferase reporter indicated that CREB1 could bind directly to FOXD2-AS1 promoter region and activate its transcription. Functional investigations revealed that knockdown of FOXD2-AS1 significantly suppressed glioma cells proliferation, migration, invasion and EMT, and promoted apoptosis. Mechanistically, our results showed that FOXD2-AS1 may act as an endogenous sponge by competing for miR-185, thereby regulating the targets of this miRNA. Taken together, our data firstly demonstrated that CREB1-induced FOXD2-AS1 contributed to glioma progression by upregulating AKT1 via competitively binding to miR-185, providing a novel strategy for targeting FOXD2-AS1 as a potential biomarker and a therapeutic target in glioma patients.
长链非编码 RNA FOXD2-AS1(FOXD2-AS1)已被报道在多种肿瘤中作为潜在的癌基因参与。然而,其在神经胶质瘤中的表达模式和生物学功能尚未被研究。在本研究中,我们发现 FOXD2-AS1 在胶质瘤组织和细胞系中均呈显著上调表达。此外,CREB1 可以直接结合到 FOXD2-AS1 启动子区域并激活其转录。高 FOXD2-AS1 表达与高级别 WHO 分级、KPS 评分和胶质瘤患者的较短生存时间显著相关。接下来,荧光素酶报告实验表明,CREB1 可以直接结合到 FOXD2-AS1 启动子区域并激活其转录。功能研究表明,FOXD2-AS1 的敲低显著抑制了神经胶质瘤细胞的增殖、迁移、侵袭和 EMT,并促进了细胞凋亡。机制上,我们的结果表明,FOXD2-AS1 可能通过与 miR-185 竞争结合作为内源性海绵体,从而调节该 miRNA 的靶标。总之,我们的数据首次表明,CREB1 诱导的 FOXD2-AS1 通过与 miR-185 竞争性结合来上调 AKT1,从而促进神经胶质瘤的进展,为靶向 FOXD2-AS1 作为神经胶质瘤患者的潜在生物标志物和治疗靶点提供了新的策略。